Characteristic | All patients (n=266) | Patients who received ICD therapy after replacement (n=29) | Patients who did not receive ICD therapy after replacement (n=237) | p Value |
---|---|---|---|---|
Age at implantation, mean±SD, years | 57±12 | 56±11 | 57±12 | 0.60 |
Age at replacement, mean±SD, years | 62±12 | 60±11 | 62±12 | 0.51 |
Female sex, n (%) | 67 (25) | 6 (21) | 61 (26) | 0.55 |
LVEF,* mean±SD, % | 27±10 | 26±14 | 28±10 | 0.50 |
QRS duration, mean±SD, ms | 138±39 | 138.3±32.5 | 137.6±39.5 | 0.92 |
QRS duration >120 ms | 150 (56) | 18 (62) | 132 (56) | 0.51 |
NYHA heart failure class, n (%) | ||||
Class I | 37 (14) | 6 (21) | 31 (13) | 0.60 |
Class II | 123 (46) | 14 (48) | 109 (46) | |
Class III | 104 (39) | 9 (31) | 95 (40) | |
Class IV | 2 (1) | 0 (0) | 2 (1) | |
Cardiomyopathy, n (%) | ||||
Ischaemic | 157 (59) | 21 (72) | 136 (57) | 0.12 |
Non-ischaemic | 109 (41) | 8 (28) | 101 (43) | |
Diabetes mellitus, n (%) | 55 (21) | 5 (17) | 50 (21) | 0.63 |
Renal insufficiency, n (%) | 59 (22) | 7 (24) | 52 (22) | 0.79 |
Medication at implantation, n (%) | ||||
ACE inhibitor | 220 (83) | 24 (83) | 196 (83) | 0.99 |
β-Blocker | 208 (78) | 19 (66) | 189 (80) | 0.08 |
Diuretic | 165 (62) | 19 (66) | 146 (62) | 0.68 |
Digoxin | 46 (17) | 6 (21) | 40 (17) | 0.61 |
Amiodarone | 41 (15) | 7 (24) | 34 (14) | 0.18 |
Type of device, n (%) | ||||
CRT-ICD | 116 (44) | 11 (38) | 105 (44) | 0.48 |
Single-chamber ICD | 91 (34) | 9 (31) | 82 (35) | |
Dual-chamber ICD | 59 (22) | 9 (31) | 50 (21) |
CAD, coronary artery disease; CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association.
*LVEF data were available for 225 patients.